Caren Deardorf - 11 Mar 2022 Form 4/A - Amendment Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
11 Mar 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
04 Apr 2022, 19:09:17 UTC
Date Of Original Report
14 Mar 2022
Previous filing
17 Feb 2022
Next filing
19 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (right to buy) Award $0 +35,000 $0.000000 35,000 11 Mar 2022 Common Stock 35,000 $19.30 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 14, 2022, the reporting person filed a Form 4 which inadvertently reported that she was granted an option to purchase 25,000 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person was granted an option to purchase 35,000 shares of common stock.
F2 The Option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the date of grant, subject to continued service as a director through each such vesting date.